Table 2.
Comparison of clinical characteristics between 13 new-onset SLE patients before and after treatment
| Baseline | After treatment | P value | |
| 24-hour urine protein in LN, mg, median (IQR)* | 1083.00 (561.50,1701.50) | 177.00 (146.00,224.50) | <0.0001 |
| ANA, U/mL, median (IQR)* | 417.30 (374.20,466.00) | 342.15 (213.30,372.40) | 0.019 |
| Anti-dsDNA, IU/mL, mean±SD† | 329.07±208.06 | 177.92±110.12 | 0.001 |
| Complement 3, g/L, mean±SD† | 0.53±0.17 | 0.82±0.18 | ＜0.001 |
| Low complement 3, n (%)‡ | 12 (92.31) | 4 (30.77) | 0.004 |
| Disease activity (SLEDAI-2K, median (IQR))* | 10.00 (9.00,12.50) | 4.00 (1.25,4.75) | <0.0001 |
| SLEDAI-2K＜4, n (%) | 0 | 10 (76.92) | |
| SLEDAI-2K 4–9, n (%) | 3 (23.08) | 3 (23.08) | |
| SLEDAI-2K 10–14, n (%) | 8 (61.54) | 0 | |
| SLEDAI-2K≥15, n (%) | 2 (15.38) | 0 |
*Non-normally distributed variables were compared using the Mann-Whitney U tests.
†Normally distributed continuous variables were compared using Student’s t-tests.
‡Categorical variables were compared using the χ2 tests and Fisher’s exact tests.